Spondyloarthritis & psoriatic arthritis
Managing Musculoskeletal Symptoms in Patients With Psoriasis: Who Should Be in the Driver’s Seat?
Authors' conclusion
This article summarizes the insightful debate, reinforcing the importance of a multidisciplinary approach to optimize patient outcomes with PsA.
Study context
- Population
- Patients with PsO at risk of or with early psoriatic arthritis (PsA) and MSK symptoms
- Comparison
- Rheumatology-led vs dermatology-led management of MSK symptoms in PsO
Methodological detailsdebate summary, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting
- Debate summary
- GRAPPA 2024 annual meeting
Main finding
As reported in the abstract
- Rheumatology view (Proft): rheumatologists should lead PsA management, given specialised training to identify inflammatory disease and use advanced imaging to differentiate PsA from mechanical MSK conditions
- Dermatology view (Savage): dermatologists often are the first healthcare providers (HCPs) to encounter emergent PsA in PsO; increasingly aware of early detection, timely intervention and data supporting "treating to intercept"
- Both: systemic barriers hinder collaborative care; patient-centred approaches addressing skin and joint manifestations are necessary
Original publication
Managing Musculoskeletal Symptoms in Patients With Psoriasis: Who Should Be in the Driver’s Seat? J Rheumatol. Published 1 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →